249 related articles for article (PubMed ID: 32857315)
21. Phase 1 study to evaluate the effects of rifampin or itraconazole on the pharmacokinetics of limertinib (ASK120067), a novel mutant-selective inhibitor of the epidermal growth factor receptor in healthy Chinese subjects.
Cao B; Huang L; Liu M; Lin H; Ma T; Zhao Y; Geng Y; Yang Y; Guo H; Li J
Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):653-664. PubMed ID: 37811634
[TBL] [Abstract][Full Text] [Related]
22. Effect of enzyme inhibition on perampanel pharmacokinetics: Why study design matters.
Gidal BE; Maganti R; Laurenza A; Yang H; Verbel DA; Schuck E; Ferry J
Epilepsy Res; 2017 Aug; 134():41-48. PubMed ID: 28535410
[TBL] [Abstract][Full Text] [Related]
23. Effects of Strong Inhibition of Cytochrome P450 3A and UDP glucuronosyltransferase 1A9 and Strong Induction of Cytochrome P450 3A on the Pharmacokinetics, Safety, and Tolerability of Soticlestat: Two Drug-Drug Interaction Studies in Healthy Volunteers.
Yin W; Dong C; Stevenson A; Lloyd V; Petrillo M; Baratta M; Hui T; Han S
Drug Metab Dispos; 2024 Feb; 52(3):180-187. PubMed ID: 38123352
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects.
Zahir H; Greenberg J; Shuster D; Hsu C; Watanabe K; LaCreta F
Clin Pharmacokinet; 2022 Nov; 61(11):1623-1639. PubMed ID: 36264536
[TBL] [Abstract][Full Text] [Related]
25. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
Tornio A; Neuvonen PJ; Backman JT
Eur J Clin Pharmacol; 2006 Aug; 62(8):645-51. PubMed ID: 16832679
[TBL] [Abstract][Full Text] [Related]
26. Effects of Itraconazole and Rifampin on the Pharmacokinetics of Mobocertinib (TAK-788), an Oral Epidermal Growth Factor Receptor Inhibitor, in Healthy Volunteers.
Zhang S; Jin S; Griffin C; Feng Z; Lin J; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1044-1053. PubMed ID: 34145979
[TBL] [Abstract][Full Text] [Related]
27. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects.
Zhang Z; Gao X; Zhang P; Li Y; Fu M; Lin H; Feng S; Shen K; Yu G; Li X
Br J Clin Pharmacol; 2023 Aug; 89(8):2561-2568. PubMed ID: 37005376
[TBL] [Abstract][Full Text] [Related]
28. Concentration-QTc Modeling of Ozanimod's Major Active Metabolites in Adult Healthy Subjects.
Briggs E; Chapel S; Zhang P; Palmisano M; Tran JQ
CPT Pharmacometrics Syst Pharmacol; 2021 Feb; 10(2):119-126. PubMed ID: 33314790
[TBL] [Abstract][Full Text] [Related]
29. Drug-Drug Interaction Study to Assess the Effect of Cytochrome P450 Inhibition and Induction on the Pharmacokinetics of the Novel Cereblon Modulator Avadomide (CC-122) in Healthy Adult Subjects.
Ogasawara K; MacGorman K; Liu L; Chen J; Carayannopoulos LN; Zhou S; Palmisano M; Li Y
J Clin Pharmacol; 2019 Dec; 59(12):1620-1631. PubMed ID: 31172535
[TBL] [Abstract][Full Text] [Related]
30. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Niemi M; Backman JT; Neuvonen M; Neuvonen PJ
Diabetologia; 2003 Mar; 46(3):347-51. PubMed ID: 12687332
[TBL] [Abstract][Full Text] [Related]
31. Effects of cytochrome P450 (CYP3A4 and CYP2C19) inhibition and induction on the exposure of selumetinib, a MEK1/2 inhibitor, in healthy subjects: results from two clinical trials.
Dymond AW; So K; Martin P; Huang Y; Severin P; Mathews D; Lisbon E; Mariani G
Eur J Clin Pharmacol; 2017 Feb; 73(2):175-184. PubMed ID: 27889832
[TBL] [Abstract][Full Text] [Related]
32. Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers.
Ridtitid W; Wongnawa M; Mahatthanatrakul W; Punyo J; Sunbhanich M
Clin Pharmacol Ther; 2002 Nov; 72(5):505-13. PubMed ID: 12426514
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs.
Nomoto M; Zamora CA; Schuck E; Boyd P; Chang MK; Aluri J; Siu YA; Lai WG; Yasuda S; Ferry J; Rege B
Br J Clin Pharmacol; 2018 May; 84(5):952-960. PubMed ID: 29341245
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
Wang P; Liu J; Tan X; Yang F; McCabe J; Zhang J
Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):397-410. PubMed ID: 37357226
[TBL] [Abstract][Full Text] [Related]
35. Effect of itraconazole and fluconazole on the pharmacokinetics of valemetostat: An open-label, phase I study in healthy subjects.
Tachibana M; Matsuki S; Maekawa Y; Kuroda K; Shimizu T; Tsutsumi J; Ishizuka H
Clin Transl Sci; 2023 Nov; 16(11):2153-2162. PubMed ID: 37705321
[TBL] [Abstract][Full Text] [Related]
36. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
[TBL] [Abstract][Full Text] [Related]
37. Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies.
Dirix L; Swaisland H; Verheul HM; Rottey S; Leunen K; Jerusalem G; Rolfo C; Nielsen D; Molife LR; Kristeleit R; Vos-Geelen J; Mau-Sørensen M; Soetekouw P; van Herpen C; Fielding A; So K; Bannister W; Plummer R
Clin Ther; 2016 Oct; 38(10):2286-2299. PubMed ID: 27745744
[TBL] [Abstract][Full Text] [Related]
38. Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Backman JT; Luurila H; Neuvonen M; Neuvonen PJ
Clin Pharmacol Ther; 2005 Aug; 78(2):154-67. PubMed ID: 16084850
[TBL] [Abstract][Full Text] [Related]
39. Effect of Itraconazole or Rifampin on Itacitinib Pharmacokinetics When Administered Orally in Healthy Subjects.
Barbour AM; Punwani N; Epstein N; Landman R; Cimino E; Yuska B; Wang P; He K; Chen X; Yeleswaram S
J Clin Pharmacol; 2019 Dec; 59(12):1641-1647. PubMed ID: 31282592
[TBL] [Abstract][Full Text] [Related]
40. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.
Tran JQ; Hartung JP; Tompkins CA; Frohna PA
Clin Pharmacol Drug Dev; 2018 Aug; 7(6):634-640. PubMed ID: 29125718
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
